Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kangfuxin is a traditional Chinese medicine approved by China's National Medical Products Administration (NMPA) and is composed solely of an ethanol extract from the dried bodies of the American cockroach, *Periplaneta americana*. [1, 3, 5] It is developed and manufactured by companies such as Sichuan Good Doctor Pharmaceutical Group. The drug is primarily used for tissue repair and wound healing and is formulated as a liquid solution for oral, topical, or rectal administration. [2, 16] Clinical studies have investigated its use for various conditions, including radiotherapy-induced oral mucositis, gastric and duodenal ulcers, ulcerative colitis, burns, and other external wounds. [2, 4, 16] Its mechanism of action includes promoting blood circulation, accelerating granulation tissue growth, and reducing inflammation. [11, 14, 16] Scientific studies suggest that it protects the intestinal mucosal barrier and alleviates colitis by inhibiting the RIP1/RIP3/MLKL-mediated necroptosis pathway and the activation of the NF-κB and NLRP3 inflammasome signaling pathways, which reduces the production of pro-inflammatory cytokines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kangfuxin.